MONTREAL, CANADA--(Marketwire - December 10, 2007) - Theratechnologies (TSX: TH) today presented its commercial evaluation of the HIV-associated lipodystrophy market based on updated market research performed by recognized third party agencies. The reported number of HIV patients for 2007 is 1.9M patients(i) in the US & Europe (G5) and this number is projected to be 2.3M patients in 2012, assuming a 3% CAGR. Combining the 2012 estimated prevalence for patients with HIV with the Company's updated market research figures, the number of patients with HIV-associated lipodystrophy, and more specifically lipohypertrophy, projected in 2012 is approximately 380,000 patients. Based on what is observed today, the projected 2012 market potential for the US and Europe for HIV-associated lipodystrophy is estimated in the range of $811M - $1.3B USD.
